Articles From: Elegant Illusions, Inc. Reports April - June 2014 Same Store and Company Wide Revenues to Elizabeth Arden Announces Intent to Evaluate Tender Offer by Affiliates of Rhône Capital


2014/8/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136108&ProfileId=051205&sourceType=1 PACIFIC GROVE, CA --
Sign-up for Elegant Illusions, Inc. Reports April - June 2014 Same Store and Company Wide Revenues investment picks
2014/6/24
STOCKHOLM , June 24, 2014 /PRNewswire/ -- Elekta has selected Birst , the global leader in cloud-based business intelligence (BI), to help clinicians, researchers and business managers exploit the potential of big data in their decision making.
Sign-up for Elekta To Bring Big Data Analytics To Oncology And Radiosurgery Registries investment picks
Monaco 5 joins latest version of MOSAIQ in spotlight at 2014 American Association of Physicists in Medicine (AAPM) Annual Meeting AUSTIN, Texas , July 16, 2014 /PRNewswire/ -- AAPM Booth #231 -- Monaco® 5 is scheduled to make its AAPM debut at the organization's 56 th Annual Meeting and Exhibition, July 20-24 in Austin, Texas .
Sign-up for Elekta's Monaco 5 treatment planning system to make its AAPM radiation physics conference debut investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0961659001&sourceType=1 http://media3.marketwire.com/logos/20140211-ele2.jpg TORONTO, ONTARIO --
Sign-up for Element Builds Structured Finance Team With the Recruitment of Senior Wall Street Veterans investment picks
2014/8/21
Elemental Energy Announces Financial Close for 11.2MW Community Wind Portfolio in Nova Scotia Canada NewsWire VANCOUVER , Aug.
Sign-up for Elemental Energy Announces Financial Close for 11.2MW Community Wind Portfolio in Nova Scotia investment picks
2014/7/1
OKLAHOMA CITY , July 1, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk Communications Corp. Announces Date of 2014 Annual Meeting of Stockholders investment picks
2014/7/31
OKLAHOMA CITY , July 31, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk Communications Corp. signs agreement to collaborate on global sales with HP investment picks
2014/6/26
Migration is the second segment of subscribers planned to migrate onto ET's Software DNA™ 2.0 Platform MEXICO CITY and OKLAHOMA CITY , June 26, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk Completes Next Migration of Iusacell Subscribers in Mexico investment picks
2014/8/21
1.75 million Iusacell subscribers migrated onto ET's Software DNA® 2.0 Platform to date MEXICO CITY and OKLAHOMA CITY , Aug.
Sign-up for Elephant Talk Completes Next Migration of Iusacell Subscribers in Mexico investment picks
2014/8/12
Adjusted EBITDA Increased to Approximately $553,000 and Quarter Margins Reach 88% on $6.9 Million of Revenue OKLAHOMA CITY , Aug.
Sign-up for Elephant Talk Reports Second Quarter Financial Results investment picks
2014/7/9
Mr. Steve Gersten Joins Capital Markets Group as Partner OKLAHOMA CITY , July 9, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk Retains Capital Markets Group as Investor Relations Counsel investment picks
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.
Sign-up for Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results investment picks
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences in September: A live webcast of the NewsMakers in the Biotech Industry Conference can be accessed from the Investors & Media section of Eleven’s website at www.elevenbio.com .
Sign-up for Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September investment picks
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference in New York on Tuesday, August 12, 2014 at 2:30 p.m. ET.
Sign-up for Eleven Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference investment picks
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report second quarter 2014 financial results on Wednesday, August 13, 2014.
Sign-up for Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014 investment picks
Elgin Mining Shareholders Overwhelmingly Approve Plan of Arrangement with Mandalay Resources Canada NewsWire TORONTO , Sept.
Sign-up for Elgin Mining Shareholders Overwhelmingly Approve Plan of Arrangement with Mandalay Resources investment picks
Anthem Blue Cross and Blue Shield and Indiana Family & Social Services Administration (FSSA)offer students insights on access to healthcare INDIANAPOLIS , June 23, 2014 /PRNewswire/ -- Students from Marian University College of Osteopathic Medicine are onsite at Eli Lilly and Company (NYSE: LLY) corporate headquarters in Indianapolis working alongside healthcare professionals in the pharmaceutical industry.
Sign-up for Eli Lilly and Company Collaborates with Public and Private Healthcare Organizations to Provide Medical Students an Opportunity to Explore Healthcare Outside the Traditional Learning Environment investment picks
2014/7/22
By William L.
Sign-up for Eliot Spitzer backs analyst-ranking firm investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Eliquis (apixaban) be granted marketing authorization for the treatment of DVT (deep vein thrombosis) and PE (pulmonary embolism), and the prevention of recurrent DVT and PE, in adults.
Sign-up for Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE investment picks
NEW YORK , Sept.
Sign-up for Elisabeth DeMarse Named To Folio:'s Inaugural List Of Top Women In Media investment picks
NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.
Sign-up for Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201 investment picks
Revenues Increase by 61%, Product Development on Schedule NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015 investment picks
Revenues Increase by 35%, Product Development Accelerating NORTHVALE, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) , a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2014 ("Fiscal 2014"). Consolidated revenues were $4.6 million for the fiscal year, an increase of $1.2 million or approximately 35% over consolidated revenues for the prior year.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014 investment picks
NORTHVALE, N.J., June 26, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) , a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide the year end business update at 12:00 PM ET on Tuesday, July 1, 2014.
Sign-up for Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014 investment picks
NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014 investment picks
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, today announced that Nightingale Onshore Holdings L.P. and Nightingale Offshore Holdings L.P., investment funds affiliated with Rhône Capital L.L.C. (referred to together as “Rhône Capital”), have commenced a partial tender offer to acquire up to 6,442,013 shares of the Company’s outstanding common stock, constituting approximately 20% of such outstanding common stock (including shares of common stock underlying warrants held by Rhône Capital), at a cash purchase price of $17.00 per share (the “Offer”). The commencement of the Offer is consistent with Rhône Capital’s previously announced intention to increase their investment in the Company following Rhône Capital’s purchase of 50,000 shares of the Company’s Series A Serial Preferred Stock and warrants to purchase 2,452,267 shares of the Company’s common
Sign-up for Elizabeth Arden Announces Intent to Evaluate Tender Offer by Affiliates of Rhône Capital investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Elegant Illusions, Inc. Reports April - June 2014 Same Store and Company Wide Revenues to Elizabeth Arden Announces Intent to Evaluate Tender Offer by Affiliates of Rhône Capital
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices